4170
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei C… Read more
4170 (4170) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.015x
Based on the latest financial reports, 4170 (4170) has a cash flow conversion efficiency ratio of -0.015x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-5.82 Million) by net assets (NT$393.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
4170 - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how 4170's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
4170 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4170 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Associated Industries China Inc
TW:9912
|
-0.114x |
|
Dongil Metal Co. Ltd
KQ:109860
|
0.015x |
|
BCM Resources Corporation
PINK:BCMRF
|
-0.002x |
|
HEBEI CONSTR.GRP CORP YC1
F:H9D
|
N/A |
|
GENOMTEC S.A. ZY -10
F:4VI
|
N/A |
|
Koil Energy Solutions Inc.
OTCQB:KLNG
|
-0.074x |
|
Netgem SA
PA:ALNTG
|
0.054x |
|
SOSANDAR PLC LS -001
F:HXKB
|
N/A |
Annual Cash Flow Conversion Efficiency for 4170 (2019–2024)
The table below shows the annual cash flow conversion efficiency of 4170 from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$389.58 Million | NT$-11.51 Million | -0.030x | -1080.69% |
| 2023-12-31 | NT$430.85 Million | NT$1.30 Million | 0.003x | -90.96% |
| 2022-12-31 | NT$441.34 Million | NT$14.70 Million | 0.033x | +123.64% |
| 2021-12-31 | NT$466.94 Million | NT$-65.79 Million | -0.141x | -31.77% |
| 2020-12-31 | NT$345.08 Million | NT$-36.90 Million | -0.107x | +42.01% |
| 2019-12-31 | NT$340.13 Million | NT$-62.72 Million | -0.184x | -- |